, Volume 16, Issue 1, pp 3–10 | Cite as

Improvements in Gene Therapy

Averting the Immune Response to Adenoviral Vectors
  • Thomas RitterEmail author
  • Manfred Lehmann
  • Hans-Dieter Volk
Gene Therapy


Gene therapy is an interesting approach for the correction of defective genes, the treatment of cancer and the introduction of immunomodulatory genes. Various techniques for gene transfer into cells or tissues have been developed within the last decade; these can be divided generally into viral and nonviral gene transfer systems. Nonviral techniques include the liposome- or gene gun-mediated introduction of therapeutic genes; however, the efficiency of gene transfer by these applications is still very low. In contrast, viruses have optimised their strategies for efficient infection of virtually any cell type in a mammalian organism. The genetic modification of genomes from different virus families (Adenoviridae, Retroviridae, Herpesviridae) led to the development of gene therapy vectors with a similar capacity to infect cells or tissues as that of wild type viruses. In contrast to wild type viruses, gene therapy vectors are engineered to transfer therapeutic genes into the target cells or tissues. In addition, they have lost their capacity for replication in target cells, because of the removal of essential genes, which allows replication only in specialised packaging cell lines engineered for the production of recombinant viruses.

Despite considerable progress over the past decade in the generation of gene transfer systems with reduced immunogenic properties, the remaining immunogenicity of many gene therapy vectors is still the major hurdle, preventing their frequent application in clinical trials.

Recombinant adenoviruses have been shown to be promising vectors for gene therapy, since they are able to transduce both quiescent and proliferating cells very efficiently. However, a major disadvantage of adenoviral vectors lies in the activation of both the innate and adaptive parts of the recipient’s immune system when applied in vivo. The inflammatory responses induced by adenovirus particles can be very strong and can be fatal in patients treated with these adenoviral constructs. Therefore, many experiments have been performed in the effort to prevent these inflammatory responses mediated by adenoviral particles. The depletion of cell populations responsible for these inflammatory responses as well as the application of immunosuppressive drugs have been investigated. Moreover, the generation of less immunogenic adenoviral vectors by further genetic modification within the adenoviral genome has led to vectors with reduced immunogenic properties. Both strategies to reduce inflammatory responses against adenoviral particles are discussed in this review.


Adenoviral Vector Recombinant Adenovirus Therapeutic Gene Wild Type Virus Helper Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Dr Alexander Flügel, Max-Planck Institute of Neurobiology, Martinsried, Germany, Grit SchrÖder, Institute of Medical Biochemistry and Molecular Biology, University of Rostock and Dr Saleh Ibrahim, Institute of Immunology, University of Rostock, Germany for critically reading the manuscript. This work has been funded in part by Deutsche Forschungsgemeinschaft (DFG) Vo489/6-1.


  1. 1.
    Graham FL. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol Today 2000 Sep; 21(9): 426–8PubMedCrossRefGoogle Scholar
  2. 2.
    Horwitz MS. Adenoviruses. In: Fields B, Knipe DM, Howley PM, et al., editors. Fields virology. Philadelphia: Lippincott-Raven, 1996: 2149–71Google Scholar
  3. 3.
    Ballay A, Levrero M, Buendia MA, et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J 1985 Dec 30; 4(13B): 3861–5PubMedGoogle Scholar
  4. 4.
    Karlsson S, Van Doren K, Schweiger SG, et al. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J 1986 Sep; 5(9): 2377–85PubMedGoogle Scholar
  5. 5.
    Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977 Jul; 36(1): 59–74PubMedCrossRefGoogle Scholar
  6. 6.
    Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996 Jan 20; 7(2): 215–22PubMedCrossRefGoogle Scholar
  7. 7.
    Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature 1997 Sep 18; 389(6648): 239–42PubMedCrossRefGoogle Scholar
  8. 8.
    Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001 Jan; 7(1): 33–40PubMedCrossRefGoogle Scholar
  9. 9.
    Nemerow GR. Cell receptors involved in adenovirus entry. Virology 2000 Aug 15; 274(1): 1–4PubMedCrossRefGoogle Scholar
  10. 10.
    Elkon KB, Liu CC, Gall JG, et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997 Sep 2; 94(18): 9814–9PubMedCrossRefGoogle Scholar
  11. 11.
    Brenner M. Gene transfer by adenovectors. Blood 1999 Dec 15; 94(12): 3965–7PubMedGoogle Scholar
  12. 12.
    Otake K, Ennist DL, Harrod K, et al. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 1998 Oct 10; 9(15): 2207–22PubMedCrossRefGoogle Scholar
  13. 13.
    Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999 Apr 10; 10(6): 965–76PubMedCrossRefGoogle Scholar
  14. 14.
    Worgall S, Wolff G, Falck-Pedersen E, et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997 Jan 1; 8(1): 37–44PubMedCrossRefGoogle Scholar
  15. 15.
    Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000 Nov; 81 Pt 11: 2605–9PubMedGoogle Scholar
  16. 16.
    Wolff G, Worgall S, van Rooijen N, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997 Jan; 71(1): 624–9PubMedGoogle Scholar
  17. 17.
    Cichon G, Schmidt HH, Benhidjeb T, et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med 1999 Sep–Oct; 1(5): 360–71PubMedCrossRefGoogle Scholar
  18. 18.
    Schmitz H, Wigand R, Heinrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol 1983 Apr; 117(4): 455–66PubMedGoogle Scholar
  19. 19.
    Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999 Sep; 6(9): 1574–83PubMedCrossRefGoogle Scholar
  20. 20.
    Ambras JL, Sridhar NR. Immunologic aspects of renal disease. JAMA 1997 Dec 10; 278(22): 1938–45CrossRefGoogle Scholar
  21. 21.
    Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999 Mar; 106(3): 347–54PubMedCrossRefGoogle Scholar
  22. 22.
    Sigal LJ, Crotty S, Andino R, et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999 Mar 4; 398(6722): 77–80PubMedCrossRefGoogle Scholar
  23. 23.
    Yang Y, Li Q, Ertl HC, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995 Apr; 69(4): 2004–15PubMedGoogle Scholar
  24. 24.
    Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995 Sep 1; 155(5): 2564–70PubMedGoogle Scholar
  25. 25.
    DeMatteo RP, Chu G, Ahn M, et al. Immunologie barriers to hepatic adenoviral gene therapy for transplantation. Transplantation 1997 Jan 27; 63(2): 315–9PubMedCrossRefGoogle Scholar
  26. 26.
    Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 1998 Apr; 72(4): 2945–54PubMedGoogle Scholar
  27. 27.
    Gagandeep S, Ott M, Sokhi RP, et al. Rapid clearance of syngeneic transplanted hepatocytes following transduction with E-l -deleted adenovirus indicates early host immune responses and offers novel ways for studying viral vector, target cell and host interactions. Gene Ther 1999 May; 6(5): 729–36PubMedCrossRefGoogle Scholar
  28. 28.
    Molinier-Frenkel V, Gahery-Segard H, Mehtali M, et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000 Aug; 74(16): 7678–82PubMedCrossRefGoogle Scholar
  29. 29.
    Yang Y, Jooss KU, Su Q, et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996 Feb; 3(2): 137–44PubMedGoogle Scholar
  30. 30.
    Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997 Nov 20; 8(17): 2019–29PubMedCrossRefGoogle Scholar
  31. 31.
    Ritter T, Brandt C, Prosch S, et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 2000 Aug; 12(8): 1163–70PubMedCrossRefGoogle Scholar
  32. 32.
    Rosenberg SA, Blaese RM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther 2000 Apr 10; 11(6): 919–79PubMedCrossRefGoogle Scholar
  33. 33.
    Alton E, Kitson C. Gene therapy for cystic fibrosis. Expert Opin Invest Drags 2000 Jul; 9(7): 1523–35CrossRefGoogle Scholar
  34. 34.
    Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 3; 100(5): 468–74PubMedCrossRefGoogle Scholar
  35. 35.
    Batshaw ML, Wilson JM, Raper S, et al. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther 1999 Sep 20; 10(14): 2419–37PubMedCrossRefGoogle Scholar
  36. 36.
    Knorr D. Serious adverse event on NIH Human Gene Transfer Protocol #9512-139. A phase I study of adenovector mediated gene transfer to liver in adults with partial ornithine transcarbamylase deficiency. Memorandum of 21 Sep 1999, Office of Recombinant DNA Activities at NIH, 1999Google Scholar
  37. 37.
    Geutskens SB, van der Eb MM, Plomp AC, et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther 2000 Aug; 7(16): 1410–6PubMedCrossRefGoogle Scholar
  38. 38.
    Chatenoud L. Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity. Mol Med Today 1998 Jan; 4(1): 25–30PubMedCrossRefGoogle Scholar
  39. 39.
    Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998; 16: 619–44PubMedCrossRefGoogle Scholar
  40. 40.
    Lei D, Lehmann M, Shellito JE, et al. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther 1996 Dec 1; 7(18): 2273–9PubMedCrossRefGoogle Scholar
  41. 41.
    Kolls JK, Lei D, Odom G, et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996 Mar 1; 7(4): 489–97PubMedCrossRefGoogle Scholar
  42. 42.
    Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996 May; 3(5): 412–20PubMedGoogle Scholar
  43. 43.
    Christ M, Lusky M, Stoeckel F, et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997 Jun 1; 57(1–3): 19–25PubMedCrossRefGoogle Scholar
  44. 44.
    Schroder G, Risch K, Nizze H, et al. Immune response after adenoviral gene transfer in syngeneic heart transplants: effects of anti-CD4 monoclonal antibody therapy. Transplantation 2000 Jul 15; 70(1): 191–8PubMedGoogle Scholar
  45. 45.
    Shean MK, Baskin G, Sullivan D, et al. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates. Hum Gene Ther 2000 May 1; 11(7): 1047–55PubMedCrossRefGoogle Scholar
  46. 46.
    Ye X, Robinson MB, Pabin C, et al. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther 2000 Oct; 7(20): 1761–7PubMedCrossRefGoogle Scholar
  47. 47.
    Kay MA, Holterman AX, Meuse L, et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995 Oct; 11(2): 191–7PubMedCrossRefGoogle Scholar
  48. 48.
    Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996 Aug 20; 7(13): 1555–66PubMedCrossRefGoogle Scholar
  49. 49.
    Yap J, O’Brien T, Tazelaar HD, et al. Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation. Cardiovasc Res 1997 Sep; 35(3): 529–35PubMedCrossRefGoogle Scholar
  50. 50.
    Ilan Y, Jona VK, Sengupta K, et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 1997 Oct; 26(4): 949–56PubMedCrossRefGoogle Scholar
  51. 51.
    Cichon G, Strauss M. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer. Gene Ther 1998 Jan; 5(1): 85–90PubMedCrossRefGoogle Scholar
  52. 52.
    Guibinga GH, Lochmuller H, Massie B, et al. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol 1998 Jun; 72(6): 4601–9PubMedGoogle Scholar
  53. 53.
    Zhang HG, Zhou T, Yang P, et al. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 1998 Sep 1; 9(13): 1875–84PubMedCrossRefGoogle Scholar
  54. 54.
    Peng Y, Trevejo J, Zhou J, et al. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol 1999 Jun; 73(6): 5098–109PubMedGoogle Scholar
  55. 55.
    Ritter T, Schroder G, Risch K, et al. Ischemia/reperfusion injury-mediated down-regulation of adenovirus-mediated gene expression in a rat heart transplantation model is inhibited by co-application of a TNFRp55-Ig chimeric construct. Gene Ther 2000 Jul; 7(14): 1238–43PubMedCrossRefGoogle Scholar
  56. 56.
    Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999; 73: 153–264PubMedCrossRefGoogle Scholar
  57. 57.
    Min B, Legge KL, Li L, et al. Neonatal tolerant immunity for vaccination against autoimmunity. Int Rev Immunol 2000; 19(2–3): 247–64PubMedCrossRefGoogle Scholar
  58. 58.
    Kishimoto H, Sprent J. The thymus and central tolerance. Clin Immunol 2000 Apr; 95(1Pt 2):S3–7PubMedCrossRefGoogle Scholar
  59. 59.
    Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest 1996 Dec 1; 98(11): 2640–7PubMedCrossRefGoogle Scholar
  60. 60.
    DeMatteo RP, Raper SE, Ahn M, et al. Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus. Ann Surg 1995 Sep; 222(3): 229–39PubMedCrossRefGoogle Scholar
  61. 61.
    Takahashi M, Ilan Y, Chowdhury NR, et al. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996 Oct 25; 271(43): 26536–42PubMedCrossRefGoogle Scholar
  62. 62.
    Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997 Mar 1; 99(5): 1098–106PubMedCrossRefGoogle Scholar
  63. 63.
    Ilan Y, Sauter B, Chowdhury NR, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998 May; 27(5): 1368–76PubMedCrossRefGoogle Scholar
  64. 64.
    Kass-Eisler A, Leinwand L, Gall J, et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996 Feb; 3(2): 154–62PubMedGoogle Scholar
  65. 65.
    Mastrangeli A, Harvey BG, Yao J, et al. ’sero-switch’ adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996 Jan; 7(1): 79–87PubMedCrossRefGoogle Scholar
  66. 66.
    Mack CA, Song WR, Carpenter H, et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997 Jan 1; 8(1): 99–109PubMedCrossRefGoogle Scholar
  67. 67.
    Moffatt S, Hays J, HogenEsch H, et al. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000 Jun 20; 272(1): 159–67PubMedCrossRefGoogle Scholar
  68. 68.
    Ostapchuk P, Hearing P. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J Virol 2001 Jan; 75(1): 45–51PubMedCrossRefGoogle Scholar
  69. 69.
    Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998 Oct; 72(10): 7909–15PubMedGoogle Scholar
  70. 70.
    Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996; 14: 101–30Google Scholar
  71. 71.
    Wiertz EJ, Mukherjee S, Ploegh HL. Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997 Mar; 3(3): 116–23PubMedCrossRefGoogle Scholar
  72. 72.
    Lee MG, Abina MA, Haddada H, et al. The constitutive expression of the immunomodulatory gpl9k protein in El-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995 Jun; 2(4): 256–62PubMedGoogle Scholar
  73. 73.
    Ilan Y, Droguett G, Chowdhury NR, et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997 Mar 18; 94(6): 2587–92PubMedCrossRefGoogle Scholar
  74. 74.
    Schowalter DB, Tubb JC, Liu M, et al. Heterologous expression of adenovirus E3-gpl9K in an Ela-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther 1997 Apr; 4(4): 351–60PubMedCrossRefGoogle Scholar
  75. 75.
    Bromberg JS, Debruyne LA, Qin L. Interactions between the immune system and gene therapy vectors: bidirectional regulation of response and expression. Adv Immunol 1998; 69: 353–409PubMedCrossRefGoogle Scholar
  76. 76.
    Varley AW, Coulthard MG, Meideil RS, et al. Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes. Proc Natl Acad Sci U S A 1995 Jun 6; 92(12): 5346–50PubMedCrossRefGoogle Scholar
  77. 77.
    Varley AW, Munford RS. Physiologically responsive gene therapy. Mol Med Today 1998 Oct; 4(10): 445–51PubMedCrossRefGoogle Scholar
  78. 78.
    Curiel DT. Considerations and challenges for the achievement of targeted gene delivery. Gene Ther 1999 Sep; 6(9): 1497–8PubMedCrossRefGoogle Scholar
  79. 79.
    Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000 May; 1 (5 Pt 1): 391–405PubMedCrossRefGoogle Scholar
  80. 80.
    Wickham TJ. Targeting adenovirus. Gene Ther 2000 Jan; 7(2): 110–4PubMedCrossRefGoogle Scholar
  81. 81.
    Wickham TJ, Roelvink PW, Brough DE, et al. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996 Nov; 14(11): 1570–3PubMedCrossRefGoogle Scholar
  82. 82.
    Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998 Dec; 72(12): 9706–13PubMedGoogle Scholar
  83. 83.
    van Beusechem VW, van Rijswijk AL, van Es HH, et al. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 2000 Nov; 7(22): 1940–6PubMedCrossRefGoogle Scholar
  84. 84.
    Xia H, Anderson B, Mao Q, et al. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000 Dec; 74(23): 11359–66PubMedCrossRefGoogle Scholar
  85. 85.
    Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997 Oct; 71(10): 7663–9PubMedGoogle Scholar
  86. 86.
    O’Neal WK, Zhou H, Morral N, et al. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alphal -antitrypsin after systemic delivery. Hum Gene Ther 1998 Jul 20; 9(11): 1587–98PubMedCrossRefGoogle Scholar
  87. 87.
    Lusky M, Grave L, Dieterle A, et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J Virol 1999 Oct; 73(10): 8308–19PubMedGoogle Scholar
  88. 88.
    Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirus vector lacking El, e2a, E3, and all of E4 except open reading frame 3. J Virol 1999 Jul; 73(7): 6048–55PubMedGoogle Scholar
  89. 89.
    Mitani K, Graham FL, Caskey CT, et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995 Apr 25; 92(9): 3854–8PubMedCrossRefGoogle Scholar
  90. 90.
    Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996 Nov 26; 93(24): 13565–70PubMedCrossRefGoogle Scholar
  91. 91.
    Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998 Feb; 18(2): 180–3PubMedCrossRefGoogle Scholar
  92. 92.
    Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alphal-antitrypsin with negligible toxicity. Hum Gene Ther 1998 Dec 10; 9(18): 2709–16PubMedCrossRefGoogle Scholar
  93. 93.
    Morral N, O’Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999 Oct 26; 96(22): 12816–21PubMedCrossRefGoogle Scholar
  94. 94.
    Morsy MA, Caskey CT. Expanded-capacity adenoviral vectors — the helper-dependent vectors. Mol Med Today 1999 Jan; 5(1): 18–24PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Thomas Ritter
    • 1
    Email author
  • Manfred Lehmann
    • 2
  • Hans-Dieter Volk
    • 1
  1. 1.Institute of Medical Immunology, CharitéHumboldt-University BerlinBerlinGermany
  2. 2.Institute of Medical Biochemistry and Molecular BiologyUniversity of RostockRostockGermany

Personalised recommendations